Vivek Ramaswamy Biography and Net Worth

Major Shareholder of Roivant Sciences

Vivek Ramaswamy is the Major Shareholder of Roivant Sciences.

What is Vivek Ramaswamy's net worth?: The estimated net worth of Vivek Ramaswamy is at least $712.79 million as of November 17th, 2025. Ramaswamy owns 33,653,756 shares of Roivant Sciences stock worth more than $712,786,552 as of December 4th. This net worth evaluation does not reflect any other investments that Ramaswamy may own. Learn More about Vivek Ramaswamy's net worth.
How do I contact Vivek Ramaswamy?: The corporate mailing address for Ramaswamy and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347 and via email at [email protected]. Learn More on Vivek Ramaswamy's contact information.
Has Vivek Ramaswamy been buying or selling shares of Roivant Sciences?: During the past quarter, Vivek Ramaswamy has sold $37,939,111.83 in Roivant Sciences stock. Most recently, Vivek Ramaswamy sold 539,650 shares of the business's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $20.51, for a transaction totalling $11,068,221.50. Following the completion of the sale, the insider now directly owns 33,653,756 shares of the company's stock, valued at $690,238,535.56. Learn More on Vivek Ramaswamy's trading history.
Who are Roivant Sciences' active insiders?: Roivant Sciences' insider roster includes Matthew Gline (CEO), Rakhi Kumar (CAO), Keith Manchester (Director), Vivek Ramaswamy (Major Shareholder), Mayukh Sukhatme (President and Chief Investment Officer), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.
Are insiders buying or selling shares of Roivant Sciences?: In the last year, Roivant Sciences insiders bought shares 2 times. They purchased a total of 16,848,325 shares worth more than $336,950,157.05. In the last year, insiders at the sold shares 43 times. They sold a total of 15,286,193 shares worth more than $220,783,629.50. The most recent insider tranaction occured on November, 19th when Director Daniel Allen Gold sold 1,300,000 shares worth more than $26,299,000.00. Insiders at Roivant Sciences own 10.8% of the company. Learn More about insider trades at Roivant Sciences.
Information on this page was last updated on 11/19/2025.

Vivek Ramaswamy Insider Trading History at Roivant Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/17/2025	Sell	539,650	$20.51	$11,068,221.50	33,653,756
11/14/2025	Sell	1,027,670	$20.33	$20,892,531.10	34,193,406
11/13/2025	Sell	287,283	$20.81	$5,978,359.23	35,221,076
9/5/2025	Sell	385,816	$12.96	$5,000,175.36	35,508,359
9/4/2025	Sell	194,933	$12.92	$2,518,534.36	35,894,175
9/3/2025	Sell	1,195,000	$12.50	$14,937,500.00	36,089,108
6/20/2025	Sell	577,007	$11.46	$6,612,500.22	37,284,108
6/18/2025	Sell	565,266	$11.45	$6,472,295.70	37,861,115
6/6/2025	Sell	200,800	$11.19	$2,246,952.00	38,426,381
6/4/2025	Sell	547,430	$11.34	$6,207,856.20	38,627,181
5/6/2025	Sell	273,959	$11.47	$3,142,309.73	39,799,611
1/2/2024	Sell	3,000,000	$11.05	$33,150,000.00	51,929,426
2/22/2023	Sell	4,000,000	$7.95	$31,800,000.00	54,409,211

Vivek Ramaswamy Buying and Selling Activity at Roivant Sciences

Roivant Sciences Company Overview

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Today's Range

Now: $21.18

$20.53

$21.33

50 Day Range

MA: $18.73

$15.10

$21.32

2 Week Range

Now: $21.18

$8.73

$21.35

Volume

6,795,330 shs

Average Volume

6,897,859 shs

Market Capitalization

$14.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22